timothy sykes logo
Scinai Immunotherapeutics SCNI Shifts Focus To NanoAb Platform Thumbnail
G Google News

Scinai Immunotherapeutics SCNI Shifts Focus To NanoAb Platform

JACK KELLOGG•UPDATED SEP. 14, 2026, 7:48 AM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

Scinai Immunotherapeutics Ltd. stocks have been trading up by 45.18 percent amid heightened optimism over its latest biotech developments.

Key Takeaways

  • The company is terminating its option and license agreements with PinCell for PC111, removing that external program from its pipeline.
  • Management is reallocating R&D capital toward Scinai’s in-house NanoAb antibody platform to tighten strategic focus.
  • Growth emphasis is shifting to CDMO arm Scinai Biopharma Services, targeting fee-based revenue.
  • SCNI is maintaining its collaboration with the Max Planck Society and University Medical Center Göttingen to support its core science.

Candlestick Chart

Live Update At 07:47:46 EDT: On Monday, September 14, 2026 Scinai Immunotherapeutics Ltd. stock [NASDAQ: SCNI] is trending up by 45.18%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SCNI has been trading like a classic biotech fade. On the daily chart, Scinai Immunotherapeutics Ltd. slid from around $3.22 on 2026/08/21 to roughly $1.66–$1.71 by 2026/09/11. That’s a steep downtrend over a few weeks, showing traders have been unloading risk and confidence has been thin.

Intraday, SCNI’s 5‑minute chart shows heavy volatility, with premarket spikes from about $2.01 at 04:00 to over $3.25, then sharp pullbacks back into the $2s. This kind of wild range tells traders the stock is liquid enough for momentum, but also unforgiving if entries are sloppy. Spikes have been getting sold into rather than held, which is typical for a speculative small-cap biotech.

More Breaking News

On fundamentals, Scinai Immunotherapeutics posted revenue of about $1.31M and trades at a low price-to-sales ratio near 0.63, plus a price-to-book around 0.34. Book value per share near 4.94 stands well above the recent share price, but returns on equity and assets are deeply negative. For traders, that screams “story stock”: the balance sheet is still there, but the market wants proof of a path to future cash flow before rewarding SCNI again.

Why Traders Are Watching SCNI’s Strategic Pivot

SCNI just made a meaningful pipeline pivot that traders should not ignore. Scinai Immunotherapeutics is terminating its option and license agreements with PinCell for PC111, effectively stepping away from that licensed dermatology asset. For a small biotech, every program counts, so dropping PC111 removes one possible future catalyst. That is the overhang near term.

But Scinai Immunotherapeutics Ltd. is not simply cutting back; it is shifting. SCNI is reallocating R&D capital toward its in-house NanoAb antibody platform. That matters because in-house platforms usually carry better economics and more control than licensed programs. If the NanoAb platform delivers compelling preclinical or clinical data, SCNI gains more upside per dollar spent than with a shared or optioned asset.

At the same time, Scinai Immunotherapeutics is leaning into its CDMO arm, Scinai Biopharma Services. CDMO work is more service-based and can create steadier, fee-for-service revenue while the core pipeline takes time to mature. For traders, this is classic “barbell” strategy: high-risk, high-reward NanoAb science on one side, potentially more stable CDMO revenue on the other.

The ongoing collaboration with the Max Planck Society and University Medical Center Göttingen gives SCNI something many micro-cap biotechs lack — credible academic partners. That can help the NanoAb story gain traction if data starts to flow. Until then, SCNI remains a volatility vehicle: the termination of PC111 raises questions, but the tighter focus on NanoAb and CDMO services sets up the next narrative leg traders will trade around.

Conclusion

SCNI is at one of those crossroads that experienced traders watch closely. Scinai Immunotherapeutics Ltd. has walked away from the PinCell PC111 option and license deals, signaling the team is done spreading capital across too many external bets. Instead, Scinai Immunotherapeutics is concentrating resources on its NanoAb antibody platform and pushing to grow Scinai Biopharma Services, the CDMO unit that can bring in service revenue while the science develops.

From a trading standpoint, that combination of strategic shift plus a beaten-down chart is potent. SCNI has already shown big intraday spikes and heavy fades, which means the stock can reward disciplined traders and punish anyone chasing blindly. The key now is simple: watch how SCNI communicates NanoAb progress, CDMO customer traction, and any updates tied to the Max Planck and University Medical Center Göttingen collaborations.

As millionaire penny stock trader and teacher Tim Sykes says, “Preparation plus patience leads to big profits.” Tim Sykes often says, “Patterns repeat because human nature doesn’t change — your job is to recognize the pattern and manage your risk.” SCNI fits that playbook. Scinai Immunotherapeutics is reshaping its story, while the chart screams caution and opportunity at the same time. For traders using this purely for education and research, SCNI remains a name to study closely, not a ticker to marry.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”